CAR T cell therapy has been established as a standard-of-care option in the second-line setting for appropriate relapsed/refractory patients with large B-cell lymphoma (LBCL).1 Some outcomes data suggest more favorable outcomes when CAR T is used in the second-line setting compared with subsequent lines of therapy.2,3 That’s why it’s important to not wait to refer and to consult with a CAR T specialist for all on-label patients—early evaluation gives patients the best opportunity to optimize outcomes.3,4

In this episode of Project Oncology, Drs. Loretta Nastoupil and Manali Kamdar sit down to discuss the evolving role of CAR T-cell therapy in relapsed or refractory LBCL, including patient eligibility, referral timing, and care coordination between referring and treatment centers.

Dr. Nastoupil is an oncologist with Southwest Oncology and CommonSpirit Mercy in Durango, Colorado. Dr. Kamdar is a Professor of Medicine and Clinical Director of the Lymphoma Program at the University of Colorado School of Medicine and the UCHealth Blood Disorders and Cell Therapies Center in Aurora, Colorado.

Dr. Nastoupil and Dr. Kamdar were compensated by Bristol Myers Squibb for their participation.

References:

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.4.2026. © …

With more treatment options than ever for metastatic castration-sensitive prostate cancer (mCSPC), applying clinical trial data in everyday practice has become increasingly complex. Understanding how differences in trial design, patient populations, and clinical endpoints influence treatment decisions is essential for delivering personalized care. Join Dr. Steve Jackson as he speaks with Drs. Jahan Aghalar and Ulka Vaishampayan about practical approaches to interpreting the evidence and tailoring therapy to the patients in front of you. Dr. Aghalar is an Adjunct Assistant Professor at NYU Grossman Long Island School of Medicine, and Dr. Viashampayan is a Professor of Internal Medicine at the University of Michigan Medical School in Ann Arbor, the Director of the Phase One Program, and co-founder of the Translational and Clinical Research Program at the Rogel Cancer Center.

Long-term management of metastatic castration-sensitive prostate cancer (mCSPC) goes beyond selecting an effective therapy—it also requires careful consideration of tolerability, drug interactions, and treatment access. Balancing these factors can help clinicians personalize care while supporting adherence and quality of life over time. Joining Dr. Charles Turck to share practical strategies for navigating these decisions and tailoring treatment to each patient's unique needs is Dr. Bilal Siddiqui. He's an Assistant Professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston.

As first-line treatment options for metastatic triple-negative breast cancer continue to expand, emerging evidence and guideline updates are reshaping treatment selection. In this expert-led discussion, Dr. Alexandria May and Dr. Neil Iyengar review the growing role of biomarker-driven decision-making and examine how data from ASCENT-03, ASCENT-04, and TROPION-Breast02 are influencing preferred treatment approaches. Dr. Iyengar is the Director of the Cancer Survivorship Program and Co-Director of the Breast Medical Oncology Program at Winship Cancer Institute at Emory University.

For patients with ALK-positive non-small cell lung cancer, staying on therapy often means staying ahead of treatment-related toxicities. Join Dr. Urs Weber, Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus, as he explores practical strategies for toxicity management, dose optimization, and shared decision-making to help support durable outcomes.

Advances in targeted therapies have dramatically improved outcomes for patients with ALK-positive non-small cell lung cancer, but new resistance challenges continue to emerge. In this episode, Dr. Urs Weber discusses how cancers adapt to treatment, why off-target resistance and histologic transformation are becoming increasingly important, and where future research may help close critical gaps in care. Dr. Weber is an Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus.

As outcomes improve for patients with ALK+ non-small cell lung cancer, attention is shifting toward therapies designed to push disease control even further. Tune in as Dr. Urs Weber examines promising agents in development and discusses the momentum driving the next phase of ALK-targeted treatment. Dr. Weber is an Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus.

This is a non-certified educational series produced and controlled by ReachMD.

As BCMA-directed therapies move into earlier lines of care, more patients with relapsed and refractory (R/R) multiple myeloma are entering a treatment space with limited consensus on optimal sequencing strategies. In this conversation with Dr. Steve Jackson, Dr. Nisha Joseph explores how disease biology, immune exhaustion, prior treatment response, and patient-specific factors can guide therapy selection in this population. She's an Associate Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta.

Over the past few decades, increasing attention has been placed on reducing the risk of patient harm within the healthcare system. Learn more about the risks that are specific to medical oncology and how current systems are addressing them with Dr. Jacob Sands and Dr. Joseph Jacobson, Senior Advisor for Quality and Patient Safety at Dana-Farber Cancer Institute.

Lung cancer patients undergoing immunotherapy may be at risk for developing life-threatening toxicities. Find out how you can manage them with Dr. Jacob Sands and Dr. Aliyah Pabani, Clinical Assistant Professor in the Department of Medicine at the University of Calgary and Director of the Alberta Immunotherapy Database.